MA33921B1 - Polypeptide de fusion dirigé contre une tumeur induite par le virus eb et mutant de la colicine ia - Google Patents

Polypeptide de fusion dirigé contre une tumeur induite par le virus eb et mutant de la colicine ia

Info

Publication number
MA33921B1
MA33921B1 MA35062A MA35062A MA33921B1 MA 33921 B1 MA33921 B1 MA 33921B1 MA 35062 A MA35062 A MA 35062A MA 35062 A MA35062 A MA 35062A MA 33921 B1 MA33921 B1 MA 33921B1
Authority
MA
Morocco
Prior art keywords
virus
directed against
fusion polypeptide
colicin
mutant
Prior art date
Application number
MA35062A
Other languages
English (en)
Inventor
Xiaoqing Qiu
Original Assignee
Protein Design Lab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protein Design Lab Ltd filed Critical Protein Design Lab Ltd
Publication of MA33921B1 publication Critical patent/MA33921B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/085—Orthoherpesviridae (F), e.g. pseudorabies virus or Epstein-Barr virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

LA PRÉSENTE INVENTION CONCERNE UN POLYPEPTIDE DE FUSION, DIRIGÉ CONTRE UNE TUMEUR INDUITE PAR LE VIRUS EB, QUI COMPORTE UN ANTICORPS OU UN ANTICORPS MIMÉTIQUE DIRIGÉ CONTRE LE VIRUS EB ET UNE COLICINE FORMANT UN CANAL IONIQUE CHOISIE PARMI E1, IA, IB, A, B, N ET LEURS MUTANTS. LA PRÉSENTE INVENTION CONCERNE ÉGALEMENT UN MUTANT DE LA COLICINE IA, QUI COMPORTE DES MUTATIONS DE G11A, H22G, A26G, V31L ET H40D. LA PRÉSENTE INVENTION CONCERNE ÉGALEMENT UN GÈNE, UN VECTEUR, UN PROCÉDÉ DE PRÉPARATION ET L'UTILISATION DU POLYPEPTIDE DE FUSION, AINSI QU'UN GÈNE ET L'UTILISATION DU MUTANT.
MA35062A 2009-12-17 2010-02-26 Polypeptide de fusion dirigé contre une tumeur induite par le virus eb et mutant de la colicine ia MA33921B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2009102428380A CN102101888B (zh) 2009-12-17 2009-12-17 一种新型抗eb病毒所致肿瘤多肽及其应用与制备方法
PCT/CN2010/070762 WO2011072501A1 (fr) 2009-12-17 2010-02-26 Polypeptide de fusion dirigé contre une tumeur induite par le virus eb et mutant de la colicine ia

Publications (1)

Publication Number Publication Date
MA33921B1 true MA33921B1 (fr) 2013-01-02

Family

ID=44154977

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35062A MA33921B1 (fr) 2009-12-17 2010-02-26 Polypeptide de fusion dirigé contre une tumeur induite par le virus eb et mutant de la colicine ia

Country Status (30)

Country Link
US (1) US8883161B2 (fr)
EP (1) EP2514768B1 (fr)
JP (1) JP5683603B2 (fr)
KR (1) KR101464842B1 (fr)
CN (1) CN102101888B (fr)
AP (1) AP3535A (fr)
AU (1) AU2010333588B2 (fr)
BR (1) BR112012017350A2 (fr)
CA (1) CA2784784C (fr)
CL (1) CL2012001609A1 (fr)
CO (1) CO6541633A2 (fr)
CR (1) CR20120329A (fr)
CU (1) CU20120096A7 (fr)
DK (1) DK2514768T3 (fr)
DO (1) DOP2012000164A (fr)
EA (1) EA030638B1 (fr)
ES (1) ES2634944T3 (fr)
GE (1) GEP20156228B (fr)
HU (1) HUE033298T2 (fr)
IL (1) IL220296A (fr)
MA (1) MA33921B1 (fr)
MX (1) MX2012006952A (fr)
NZ (1) NZ600729A (fr)
PE (1) PE20121722A1 (fr)
PH (1) PH12012501134A1 (fr)
SG (1) SG181553A1 (fr)
TN (1) TN2012000253A1 (fr)
UA (1) UA104933C2 (fr)
WO (1) WO2011072501A1 (fr)
ZA (1) ZA201205217B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9200251B1 (en) 2011-03-31 2015-12-01 David Gordon Bermudes Bacterial methionine analogue and methionine synthesis inhibitor anticancer, antiinfective and coronary heart disease protective microcins and methods of treatment therewith
DK2789632T3 (en) * 2011-12-08 2018-08-06 Protein Design Lab Ltd HOW TO UNKNOWN METHOD FOR PRODUCING ANTIBIOTICS AND PLATFORM SYSTEM BASED ON THESE
WO2016023491A1 (fr) * 2014-08-12 2016-02-18 The University Of Hong Kong Composés biophosphonates et thérapie médiée par des cellules t gamma delta pour traiter des troubles associés au virus d'epstein-barr
CN104604799B (zh) * 2015-02-05 2017-11-21 南华大学 一种鉴定eb病毒对淋巴瘤的诱发性的方法
CN113227790A (zh) * 2018-11-19 2021-08-06 拜尔阿斯特公司 用于多重结合实验的方法及试剂
CN111333724B (zh) * 2018-12-19 2022-03-15 中国人民解放军军事科学院军事医学研究院 一种抗金黄色葡萄球菌肠毒素b的单克隆抗体yg11-1及其应用
CN111848817B (zh) * 2020-07-28 2021-11-09 中国农业大学 一种兼具抗菌、抗病毒、免疫调节和抗炎活性的多功能杂合肽及其制备方法和应用
CN112125959B (zh) * 2020-10-10 2022-07-29 中山大学肿瘤防治中心 一种抑制eb病毒的肽和编码该肽的dna及其应用
CN113880914B (zh) * 2021-04-25 2023-11-21 内蒙古农业大学 一种抗肿瘤多肽及其衍生物
CN114369158B (zh) * 2021-09-28 2024-04-19 北京亦科信息菌素研究院有限公司 一种抗新冠病毒的信息菌素及其应用
CN113999304B (zh) * 2021-10-13 2023-10-24 北京市农林科学院 抗肠菌素单克隆抗体mAb4及其在肠菌素检测中的应用
CN119798448B (zh) * 2024-05-10 2025-11-07 成都一棵树未来医药科技有限公司 一种抗小细胞肺癌的信息菌素阵列及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1164612C (zh) 2001-09-11 2004-09-01 四川新泰克控股有限责任公司 人工组合的抗菌工程多肽及其制备方法
CN1314806C (zh) * 2005-01-14 2007-05-09 四川大学 小型化抗eb病毒肿瘤多肽及其应用与制备方法
CN1274829C (zh) * 2004-12-10 2006-09-13 四川大学华西医院 抗eb病毒所致肿瘤多肽及其应用与制备方法
WO2007083175A1 (fr) * 2006-01-17 2007-07-26 West China Hospital, Sichuan University Molécules antivirales bifonctionnelles, procédés pour les produire et procédés pour traiter un cancer induit par virus au moyen de celles-ci
CN101643501B (zh) 2008-11-07 2012-06-20 畿晋庆三联（北京）生物技术有限公司 一种新型抗生素及其核苷酸序列、制备方法与应用
CN101633699B (zh) * 2009-09-02 2012-02-15 畿晋庆堂国际生物技术有限公司 一种含抗体模拟物的新型抗生素及其制备方法与应用

Also Published As

Publication number Publication date
CN102101888B (zh) 2013-03-20
HUE033298T2 (en) 2017-11-28
PH12012501134A1 (en) 2012-11-05
DOP2012000164A (es) 2012-12-31
CU20120096A7 (es) 2012-07-31
EP2514768A1 (fr) 2012-10-24
IL220296A0 (en) 2012-07-31
IL220296A (en) 2017-07-31
NZ600729A (en) 2014-12-24
KR101464842B1 (ko) 2014-11-27
CN102101888A (zh) 2011-06-22
WO2011072501A1 (fr) 2011-06-23
US20130066051A1 (en) 2013-03-14
SG181553A1 (en) 2012-07-30
ZA201205217B (en) 2013-03-27
AP2012006327A0 (en) 2012-06-30
HK1159123A1 (en) 2012-07-27
GEP20156228B (en) 2015-01-26
AP3535A (en) 2016-01-13
AU2010333588A1 (en) 2012-06-21
CU23931B1 (fr) 2013-06-28
EA030638B1 (ru) 2018-09-28
US8883161B2 (en) 2014-11-11
KR20120117826A (ko) 2012-10-24
DK2514768T3 (en) 2017-07-17
JP5683603B2 (ja) 2015-03-11
CO6541633A2 (es) 2012-10-16
CL2012001609A1 (es) 2012-12-07
AU2010333588B2 (en) 2013-05-02
CA2784784C (fr) 2017-10-03
EP2514768A4 (fr) 2013-12-04
CR20120329A (es) 2012-10-23
EP2514768B1 (fr) 2017-04-05
CA2784784A1 (fr) 2011-06-23
BR112012017350A2 (pt) 2018-07-24
EA201270655A1 (ru) 2012-12-28
PE20121722A1 (es) 2012-12-15
TN2012000253A1 (en) 2013-12-12
ES2634944T3 (es) 2017-09-29
JP2013514060A (ja) 2013-04-25
UA104933C2 (uk) 2014-03-25
MX2012006952A (es) 2012-10-03

Similar Documents

Publication Publication Date Title
MA33921B1 (fr) Polypeptide de fusion dirigé contre une tumeur induite par le virus eb et mutant de la colicine ia
CA3156451A1 (fr) Anticorps ayant une specificite pour la nectine -4 et leurs utilisations
SG10201405377XA (en) Compositions and methods for antibodies targeting complement protein c5
AU2017204797B2 (en) Antibodies with modified isoelectric points
MA37407A1 (fr) Anticorps dirigés contre les ligands des récepteurs b1 de la bradykinine
MA33276B1 (fr) Anticorps spécifiques à la cadhérine-17
SG10201914119TA (en) Anti-b7-h3 antibodies and antibody drug conjugates
MA34461B1 (fr) Anticorps anti-peptide beta-amyloide n3pgiu et leurs utilisations
EP4650371A3 (fr) Préparation contenant un anticorps
MA38194B1 (fr) Anticorps anti-ceacam5 et leurs utilisations
NZ607996A (en) Substituted nucleotide analogs
NZ605873A (en) Methods and compositions for cns delivery of arylsulfatase a
WO2011130749A3 (fr) Identification de mutations dans les glycoprotéines d'enveloppe de virus herpès simplex qui permettent ou augmentent le reciblage de vecteur vers de nouveaux récepteurs non-hsv
MX2009004532A (es) Composiciones y metodos para unir esfingosina-1-fosfato.
MX348578B (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer.
MX2012008999A (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX342291B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
MX340016B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
TW200714290A (en) Anti-M-CSF antibody compositions having reduced levels of endotoxin
MA31984B1 (fr) Formulation d'anticorps
MX2013001613A (es) Métodos y composiciones para prevenir una afección.
WO2011071574A3 (fr) Anticorps monoclonaux dirigés contre la glycoprotéine du virus ebola souche soudan boniface
IN2014KN02933A (fr)
IN2012DN00801A (fr)
WO2006074346A3 (fr) Modulation d'arn interferent du virus respiratoire syncytial et utilisations therapeutiques de cette modulation